A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

NCT07585747 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Tafasitamab
DRUG: Lenalidomide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China